

Neumotórax desarrollado durante el curso de una neumonía por SARS-CoV-2

Pneumothorax developed during the course of SARS-CoV-2 pneumonia

CASE REPORT

Coronavirus disease 2019 (COVID-19) is a recent outbreak in mainland China and has rapidly spread to multiple countries worldwide^{1,2}.

The largest case series of chest imaging described multilobar involvement of rounded and peripheral airspace opacities. The occurrence of pneumothorax is rare in SARS-CoV-2 pneumonia³⁻⁵.

We are reporting a case of a male who developed a pneumothorax secondary to SARS-CoV-2 pneumonia.

We present a 70-year-old male patient who was admitted to Emergency Department complaining of productive cough with mucopurulent sputum, dyspnea, fever with maximum temperature of 38.4°C and diarrhea for seven days. He had no smoking or alcohol consumption. He didn't have contact with anyone known to have COVID-19. His personal pathological history included hypertension, type 2 diabetes mellitus and dyslipidemia. He denied known structural pulmonary pathology. On physical examination, the patient was febrile (38.6°C), peripheral oxygen saturation (SpO₂) was 88% in room air and a rude vesicular murmur and bilateral intermittent wheezing were identified.

Pertinent laboratory results showed increased inflammatory parameters (leukocytosis of 10,4x10⁹ cells/L with neutrophilia of 91% and CRP of 32mg/dl) and acute kidney injury (creatinine 1,95 mg/dl and urea 100 mg/dl). Arterial gasometry with FiO₂ 24% revealed acute type 1 respiratory failure, with PaO₂ 73mmHg. Chest radiograph showed right lower lobe interstitial infiltrate (image 1) and chest computed tomography (CT) scan showed bilateral ground glass opacities and extensive areas of alveolar consolidation with air-bronchogram. Influenza A and B were negative, as well as Legionella pneumoniae antigenuria and serology for Mycoplasma pneumoniae. Oropharyngeal and nasopharyngeal swab test for SARS-CoV-2 by qualitative real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay was positive.

The patient started empirical antibiotherapy with ceftriaxone and azithromycin as well as hydroxychloroquine and lopinavir/ritonavir.

On the 5th day of hospitalization, the patient was on a 31% ventury mask. His chest radiograph which showed a spontaneous left pneumothorax, and therefore a 16F caliber chest tube was placed in the 5th left intercostal space. Total pulmonary re-expansion was observed 48 hours later, and chest tube was removed.

The patient was discharged after 3 weeks of hospitalization without further respiratory complications.

REFERENCES

1. Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020;395(10223):514-523.
2. who.int [Internet]. World Health Organization; c2020 [updated 2020 Jan 21; cited 2020 Mar 16]. Available from <https://www.who.int>
3. Salehi S, Abedi A, Balakrishnan S, Gholamrezaezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *AJR Am J Roentgenol*. 2020;215(1):87-93.
4. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology*. 2020;295(1):202-207.
5. Sun R, Liu H, Wang X. Mediastinal Emphysema, Giant Bulla, and Pneumothorax Developed during the Course of COVID-19 Pneumonia. *Korean J Radiol*. 2020;21(5):541-544.

Image 1




Image 2



Palabras clave: COVID-19, coronavirus, neumonía, complicación, neumotórax
Keywords: COVID-19, coronavirus, pneumonia, complication, pneumothorax.

Maria Inês Ferreira, Luís Carreto

Serviço de Pneumologia. Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal

Correspondencia: mferreira7@campus.ul.pt

Cómo citar este artículo: Maria Inês Ferreira, Luís Carreto

Neumotórax desarrollado durante el curso de una neumonía por SARS-CoV-2. *Galic Clin* 2021; 82-1: 51

Recibido: 15/4/2020; Aceptado: 20/1/2021 // <https://doi.org/10.22546/60/2294>